The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.
Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.
Arvinas Inc (NASDAQ:ARVN)
- On March 11, Arvinas announced topline results from the phase 3 VERITAC-2 Trial of Vepdegestrant Monotherapy versus Fulvestrant in adults with advanced or retastatic breast cancer. The company’s stock fell around 53% over the past month and has a 52-week low of $7.91.
- RSI Value: 25.9
- ARVN Price Action: Shares of Arvinas fell 5.6% to close at $8.13 on Tuesday.
Simulations Plus Inc (NASDAQ:SLP)
- Simulations Plus will report second quarter fiscal 2025 financial results after the market close on Thursday, April 3. The company’s stock fell around 19% over the past month and has a 52-week low of $24.00.
- RSI Value: 29.7
- SLP Price Action: Shares of Simulations Plus fell 3.2% to close at $24.72 on Tuesday.
- Benzinga Pro’s charting tool helped identify the trend in SLP stock.
Iovance Biotherapeutics Inc (NASDAQ:IOVA)
- On March 21, Iovance Biotherapeutics reported inducement grants under NASDAQ listing rule 5635(c)(4). The company’s stock fell around 35% over the past month and has a 52-week low of $3.42.
- RSI Value: 26.7
- IOVA Price Action: Shares of Iovance Biotherapeutics fell 4.1% to close at $3.48 on Tuesday.
- Benzinga Pro’s signals feature notified of a potential breakout in IOVA shares.
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare.
Read This Next:
